



USA-400

PAHO/WHO Collaborating Centre for Vaccine Research, Evaluation and Training on Emerging Infectious Diseases

Authors: Alan DT Barrett, PhD; David WC Beasley, PhD; and Gregg N Milligan, PhD

Department/Division, Institution: Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA

How this Collaborating Centre is contributing to the achievement of the SDGs

- Activities of this CC are primarily related to SDG 3 - Good Health and Wellbeing
- Our major role is to track and document progress on global vaccine development efforts against emerging infectious diseases. We have published six position papers related to this role (Zika, Lassa fever, Chikungunya, severe fever with thrombocytopenia syndrome, yellow fever, and Nipah. The publications are shown in the deliverables below.
- Recently, in collaboration with WHO, we are partnering to provide inputs to baseline situation analyses, TPPs and/or R&D roadmaps to be developed for specific priority pathogens as indicated by WHO. At present we are actively participating on the WHO Zika R&D Roadmap with Virginia Benassi, L.L.M. and Marie-Pierre Preziosi, M.D., Ph.D. (both with Initiative for Vaccine Research, WHO). This activity began in July 2019 and is co-directed as a partnership between members of the Zika Roadmap Steering Committee (SC) comprised of: the WHO R&D Blueprint Roadmaps team (Virginia Benassi and Marie-Pierre Preziosi), the UTMB CC (Alan Barrett, David Beasley, and Gregg Milligan); and the University of Minnesota Center for Infectious Disease Research and Policy (Anje Mehr, Kristine Moore, Michael Osterholm, and Julie Ostrowsky).

Deliverables

1. Position papers published:
2. Dawes BR, Smalley CA, Tiner BL, Beasley DWC, Milligan GN, Reece LM, Hombach J and Barrett ADT. Research and Development of Zika Virus Vaccines. NPJ Vaccines 1, 16007; Epub 2017. doi:10.1038/npjvaccines.2016.07
3. Hallam HJ, Hallam S, Rodriguez SE, Barrett ADT, Beasley DWC, Chua A, Ksiazek TG, Milligan GN, Sathiyamoorthy V, Reece LM. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines. 2018 Mar 20;3:11. doi: 10.1038/s41541-018-0049-5. eCollection 2018. Review. PMID: 29581897
4. Milligan GN, Schnierle BS, McAuley AJ, Beasley DWC. Defining a correlate of protection for chikungunya virus vaccines. Vaccine. 2019 Nov 28;37(50):7427-7436. doi: 10.1016/j.vaccine.2018.10.033. Epub 2018 Nov 15. PMID: 30448337
5. Bopp NE, Kaiser JA, Strother AE, Barrett ADT, Beasley DWC, Bennassi V, Milligan GN, Preziosi MP, Reece LM. Baseline mapping of severe fever with thrombocytopenia syndrome virology, epidemiology and vaccine research and development. NPJ Vaccines. 2020 Dec 17;5(1):111. doi: 10.1038/s41541-020-00257-5. PMID: 33335100
6. Staples JE, Barrett ADT, Wilder-Smith A, Hombach J. Flipping the paradigm: Are booster doses of yellow fever vaccine needed? NPJ Vaccines 2020 Jul 6;5:54. doi: 10.1038/s41541-020-0205-6. eCollection 2020. PMID: 32655896
7. Johnson KN, Levine CB, Read CM, Barrett ADT, Beasley DWC, Reece LM, Milligan GM. Baseline Situation analysis for Nipah virus, epidemiology, and vaccine research and development. NPJ Vaccines, in revision

Recommendations

1. Continual monitoring and evaluation of potential emerging pathogens is a critical component of ensuring healthy lives and promoting well-being for people at all ages.

Terms of Reference

1. To track progress and provide analysis of the vaccine pipeline against emerging infectious diseases
2. To conduct research on the development, evaluation and use of vaccines against emerging infectious diseases of public health importance
3. To provide education and training for future investigators in the field of vaccinology